PR91148

BEIJING, Aug. 16, 2021 /PRNewswire=KYODO JBN/ --

Sino Biological, Inc. ("Sino Biological" or the "Company"), a biotechnology

company which provides biological research reagents and related technical

contract research services, announced a successful listing on the Shenzhen

Stock Exchange subsidiary ChiNext under the stock abbreviation Sino Biological

and stock code 301047. A total of 17 million shares were issued for a total of

4.98 billion RMB raised during this initial public offering.

Sino Biological's successful listing on the capital market is an important

milestone in its strategic plan for growth. While justifying its current

business model and portfolio, this offering also conveys a new starting point

for the company's future growth and development, providing the financial

backing for broad and rapid expansion of Sino Biological's existing

capabilities. Dr. Liangzhi Xie, Chairman of Sino Biological, expressed in his

speech at the listing ceremony that, through this offering, "Sino Biological

will now be able to further enhance its strength in as one of the world's

leading providers of research reagents and services, while simultaneously

improving its competitiveness and profitability. These endeavors will bring

multiple benefits to investors such as increased shareholder value while

positively impacting the health and well-being of society."

As a high-tech enterprise, Sino Biological specializes in the research,

development, production and sales of biological reagents such as recombinant

proteins, antibodies, genes and culture media.  The company also provides

related technical contract research services, including the development of

recombinant proteins and antibodies as well as biological analysis and testing.

With a number of advanced core technologies, Sino Biological has established a

complete technology platform covering research, development, scale-up

production, and quality control so as to guarantee the high-throughput and

efficient generation of biological reagents. The company's offering helps to

drive advances in the understanding of such fields as molecular biology, cell

biology, immunology, developmental and stem cell biology and promotes the

research and development of innovative drugs and diagnostic tests.

In the future, Sino Biological will broaden efforts in the innovation,

expansion and optimization of existing product and service lines.  This will be

accomplished through internal development and acquisition of key technologies

coupled with aggressive infrastructure growth, which will enhance the company's

core competitiveness and drive towards fulfilling Sino Biological's mission to

advance life science and improve human health.

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the

meaning of the Private Securities Litigation Reform Act. These statements are

based on management's current expectations and are subject to uncertainty and

changes in circumstances. Sino Biological assumes no obligation to update these

forward-looking statements and do not intend to do so. More information is

contained in Sino Biological's filings with the Shenzhen Stock Exchange.

Contacts: Sino Biological, Inc., ir@sinobiological.cn

SOURCE  Sino Biological, Inc.

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=398483

   Caption: The Listing Ceremony